Aclaris’ Stock Crashes after Lead Asset Fails Mid-Stage Trial

Pennsylvania-based Aclaris Therapeutics will stop development of zunsemetinib after it failed to meet the primary endpoint in a Phase II study for rheumatoid arthritis.